Phase I study of vintriptol, a tryptophan ester of vinblastine

Hendrika M. Oosterkamp(The Netherlands Cancer Institute), W.W. ten Bokkel Huinink, Olaf van Tellingen(Dutch Cancer Society), Jos H. Beijnen(The Netherlands Cancer Institute), L.Th Vlasveld(The Netherlands Cancer Institute), H. R. Franklin(European Organisation for Research and Treatment of Cancer), J. Wanders(Eisai (United Kingdom)), Jan B. Vermorken(University of Antwerp), G. Simonetti(The Netherlands Cancer Institute), Anne-Charlotte Dubbelman
European Journal of Cancer and Clinical Oncology
October 1, 1991
10.1016/0277-5379(91)90085-r
Cited by 8

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
|The Lancet|2011|1.1k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884